Vincerx Pharma, Inc.
VINCDelisted Apr 28, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001796129
Vincerx Pharma, Inc. was delisted on Apr 28, 2025; its insiders filed their last Form 4 on Aug 14, 2024; 14 institutions reported holding it in 13F filings for Q1 2025, worth $116.8K in total; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in Vincerx Pharma, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- −5 vs. Q3 2024
- Shares held
- 4.80M
- −6.22M (−56.4%) vs. Q3 2024
- Total value
- $1.26M
- −$6.63M (−84.0%) vs. Q3 2024
- New holders
- 2
- 4 more added
- Sold out
- 7
- 8 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VINC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 1 | $2 |
| Q1 2025 | 14 | $116.8K |
| Q4 2024 | 21 | $1.26M |
| Q3 2024 | 26 | $7.89M |
| Q2 2024 | 28 | $8.66M |
| Q1 2024 | 38 | $42.7M |
| Q4 2023 | 33 | $11.6M |
| Q3 2023 | 35 | $10.8M |
| Q2 2023 | 34 | $15.7M |
| Q1 2023 | 35 | $13.3M |
| Q4 2022 | 34 | $13.0M |
| Q3 2022 | 43 | $20.0M |
| Q2 2022 | 49 | $18.4M |
| Q1 2022 | 65 | $65.1M |
| Q4 2021 | 55 | $156.8M |
| Q3 2021 | 55 | $248.9M |
| Q2 2021 | 56 | $157.3M |
| Q1 2021 | 36 | $171.0M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Vincerx Pharma, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| JPMorgan Chase & Co | 23 | $6 | 0.00% | −35−60.3% | Reduced |
| Bank of America Corp | 237 | $62 | 0.00% | +26+12.3% | Added |
| Bank & Trust Co | 1,000 | $263 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 1,000 | $263 | 0.00% | +1,000 | New |
| Morgan Stanley | 2,090 | $549 | 0.00% | +340+19.4% | Added |
| Colony Group, LLC | 10,900 | $2.87K | 0.00% | +10,900 | New |
| Jane Street Group, LLC | 11,190 | $2.94K | 0.00% | −9,715−46.5% | Reduced |
| Susquehanna International Group, LLP | 21,371 | $5.62K | 0.00% | −10,609−33.2% | Reduced |
| Renaissance Technologies LLC | 22,100 | $5.81K | 0.00% | −43,901−66.5% | Reduced |
| Northern Trust Corp | 34,297 | $9.01K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 47,080 | $12.4K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 57,016 | $15.0K | 0.00% | 00.0% | Unchanged |
| HRT Financial LP | 59,804 | $15.0K | 0.00% | +45,103+306.8% | Added |
| UBS Group AG | 92,779 | $24.4K | 0.00% | +92,541+38,882.8% | Added |
| Rubric Capital Management LP | 116,873 | $30.7K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 241,517 | $63.5K | 0.00% | −9,283−3.7% | Reduced |
| Vanguard Group Inc | 286,372 | $75.3K | 0.00% | −341,070−54.4% | Reduced |
| Armistice Capital, LLC | 567,011 | $149.0K | 0.00% | −2,136,989−79.0% | Reduced |
| Goldman Sachs Group Inc | 631,397 | $165.9K | 0.00% | −270.0% | Reduced |
| Rock Springs Capital Management LP | 891,719 | $234.3K | 0.01% | 00.0% | Unchanged |
| Sage Rhino Capital LLC | 1,703,413 | $447.7K | 0.10% | 00.0% | Unchanged |
| Prosight Management, LP | 0 | $0 | 0.00% | −2,206,505−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −674,193−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −542,021−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −353,562−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −18,320−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −14,227−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −6,989−100.0% | Sold out |